Of particular relevance regarding potential immune adjuvant therapy for COVID-19 are the ELISpot results showing that ex vivo IL-7 increased IFN-ɣ production of stimulated T cells nearly 2-fold (Figure 8). The gene discussed is IL7; the disease is COVID-19.